Alterations of biomarker profiles after neoadjuvant chemotherapy in breast cancer: tumor heterogeneity should be taken into consideration

Tumor biomarkers including estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) and Ki-67 are routinely tested in breast cancer patients and their status guides clinical management and predicts prognosis. A few retrospective studies have suggested that...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Xingchen, Zhang, Junyong, Yun, Haiqin, Shi, Ranran, Wang, Yan, Wang, Wei, Lagercrantz, Svetlana Bajalica, Mu, Kun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4742218/
https://www.ncbi.nlm.nih.gov/pubmed/26384297

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4742218/
https://www.ncbi.nlm.nih.gov/pubmed/26384297

Ejemplares similares